

HR 2685

Medicare Prescription Drug Price Negotiation Act

Congress: 109 (2005–2007, Ended)

Chamber: House

Policy Area: Health

Introduced: May 26, 2005

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 17, 2005)

Official Text: <https://www.congress.gov/bill/109th-congress/house-bill/2685>

Sponsor

Name: Rep. Larson, John B. [D-CT-1]

Party: Democratic • State: CT • Chamber: House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Grijalva, Raúl M. [D-AZ-7]	D · AZ		May 26, 2005
Rep. Hinchey, Maurice D. [D-NY-22]	D · NY		May 26, 2005
Rep. Doggett, Lloyd [D-TX-25]	D · TX		Sep 14, 2006

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 17, 2005
Ways and Means Committee	House	Referred to	Jun 6, 2005

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Medicare Prescription Drug Price Negotiation Act - Requires each participating manufacturer of a covered outpatient drug to make such drugs available for purchase by any qualified Federal health care provider, by each pharmacy, and by each provider of services, physician, practitioner, and supplier under the Medicare program at a price that the Secretary of Health and Human Services, in conjunction with the Secretary of Defense and the Secretary of Veterans Affairs, negotiates with the manufacturer. Provides that the amount of such a drug made available for purchase is equal to the sum of the aggregate amounts of the drug dispensed by pharmacies to Medicare beneficiaries plus the aggregate amounts dispensed through qualified Federal health care providers.

Requires the Secretary, in conducting negotiations with participating manufacturers, to take into account the goal of promoting the development of breakthrough drugs.

Requires the United States to exclude from Government contracting and subcontracting, for a period of time, a manufacturer of drugs or biologicals that does not comply with this Act.

Directs the Secretary to establish a mechanism (such as an ombudsman) for the resolution of disputes between Medicare beneficiaries and prescription drug resellers and drug manufacturers in order to protect such beneficiaries and to ensure that: (1) prescription drug resellers are not artificially increasing prices charged to Medicare beneficiaries (above those negotiated under this Act) in places (such as rural areas) where there is less competition; and (2) such resellers are not colluding on prices in areas with more potential significant competition.

---

### **Actions Timeline**

- **Jun 17, 2005:** Referred to the Subcommittee on Health.
- **Jun 6, 2005:** Referred to the Subcommittee on Health.
- **May 26, 2005:** Introduced in House
- **May 26, 2005:** Introduced in House
- **May 26, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **May 26, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **May 26, 2005:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.